Adaptive Biotechnologies

We are a global technology company that has evolved far beyond our origins in photographic film. Today, we operate across healthcare, electronics, business innovation, and imaging, with over 70,000 employees worldwide working to deliver 'Value from Innovation.' Our healthcare segment spans diagnostic imaging, endoscopic imaging, medical systems, regenerative medicine, and life sciences - supporting everything from early disease detection to biopharmaceutical development and manufacturing. In biotechnology specifically, we operate contract development and manufacturing organization (CDMO) services, helping partners develop and produce vaccines, gene therapies, and other biologics. We bring deep expertise in lipid nanoparticles, liposomes, mRNA synthesis, and advanced manufacturing technologies. Our facilities in Denmark, the United States, and other global locations provide GMP manufacturing capabilities, while our commitment to sustainability includes powering sites with 100% renewable energy.

In 2017, PROTOS Technologie was born from a simple but powerful insight: after participating in over 50 cloud migration projects at leading consulting firms and technology companies, founders Sebastian Ullrich and Andreas Sass recognized that organizations needed more than just advice - they needed a true partner who would roll up their sleeves and work alongside them. They built PROTOS to guide companies through every stage of their cloud journey, from initial strategy through implementation and beyond, combining deep technical expertise with a hands-on mentality that makes complex transformations feel manageable. Today, PROTOS has evolved into a certified AWS Advanced Consulting Partner with offices in Berlin and Hamburg, serving clients across Germany with a comprehensive suite of cloud services. The company specializes in crafting tailor-made architectures for secure IT infrastructure transformations, managing entire migration processes with precision, and implementing intelligent automation and cloud-native applications. What sets PROTOS apart is their DNA - they live and breathe cloud technology, bringing both technological craftsmanship and the cultural change management needed to help organizations truly embrace the cloud. Whether it's public transport systems, e-mobility platforms, or enterprise IT operations, PROTOS brings clear prioritization, proven methodologies, and the commitment to ensure every cloud project becomes a resounding success.

At Aerotech, we believe precision engineering is at the heart of global innovation. As an employee-owned company, every team member has a stake in our success, creating a culture where we promote from within and value every voice. Our engineers work in a clean, climate-controlled environment, tackling challenges that span from life-saving medical devices to tools for deep space exploration. We provide continuous paid on-the-job training because we believe investing in our people is investing in our future. What sets Aerotech apart is our commitment to solving the toughest precision motion and automation challenges. For over 50 years, we've designed and manufactured motion control systems that help our customers manufacture and measure products with greater accuracy. Our collaborative environment encourages engineers to debug complex problems together, implement new features, and participate in all phases of the software development life cycle. We don't just build technology - we enable our customers to push the boundaries of what's possible in semiconductor manufacturing, laser processing, medical and life sciences, and beyond.

At Ontada, we believe that transforming cancer care requires speed and precision - and that starts with our people. Our team of data scientists, researchers, and healthcare professionals work at the intersection of oncology and technology, driven by a shared mission to improve patient outcomes. We foster a collaborative environment where expertise from clinical practice meets cutting-edge analytics, enabling us to deliver real-world insights that make a difference in the fight against cancer. Our culture emphasizes curiosity and innovation, encouraging team members to bring bold ideas to solve complex healthcare challenges. As part of McKesson Corporation, we combine the stability of an industry leader with the agility of a focused mission-driven organization. Our professionals thrive here because they see the direct impact of their work - whether it's through our proprietary iKnowMed EHR serving 2,700+ oncology providers, our research expertise spanning 400+ publications, or our partnerships with all top 15 global life sciences companies. We prioritize continuous learning, collaboration across disciplines, and a commitment to excellence that reflects the urgency of our mission in oncology care.

Protecht has redefined the way the world thinks about risk management for over 20 years. The company provides the most complete, cutting-edge and cost-effective solutions that help organizations increase performance and achieve strategic objectives through better understanding, monitoring and management of risk. Protecht unifies risk, compliance and resilience in one intelligent AI platform that enables organizations to act faster and with certainty. Founded in 1999 by David Bergmark and David Tattam, Protecht delivers a complete solution comprised of world-class enterprise risk management, compliance, training and advisory services to businesses, regulators and governments across the globe. The company's Protecht.ERM platform is one of the most comprehensive, flexible and dynamic risk management solutions available today. With recent introduction of Cognita AI, Protecht combines deep risk expertise with proven AI safety to deliver intelligent automation that enhances decision-making rather than disrupting it. The company is headquartered in Sydney with operations spanning APAC, the UK and North America.

In 2013, Formation Bio was founded with a clear mission: to bring new treatments to patients faster and more efficiently. The founders recognized a critical bottleneck in drug development - while biotech innovation and AI were generating new drug candidates at an unprecedented pace, the process of developing these drugs was becoming exponentially more expensive and time-consuming. This widening gap between scientific discovery and patient access needed to be bridged. Formation Bio began as TrialSpark, initially focused on building clinical trial technology tools and operating as a CRO before evolving to acquire and develop its own drug portfolio. In December 2023, the company rebranded to Formation Bio to reflect its expanded vision. Today, the company operates as an AI-native pharma company that acquires clinical-stage drugs from pharmaceutical companies, universities, and biotech firms, developing them through a proprietary technology platform. By bringing together the best of tech and pharma - deep expertise in drug selection, drug development, and software engineering - Formation Bio optimizes all aspects of clinical drug development. The company integrates AI and data-driven approaches across the entire development lifecycle, from drug acquisition to NDA submission, enabling more efficient trial design, faster trial completion, and higher quality data capture.